The scourge of EPS: have atypical antipsychotics solved the problem?
D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000453:epidemiology*; D002986:Clinical Trials as Topic; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D009069:Movement Disorders / Q000453:epidemiology / Q000209:etiology; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D000069348:Quetiapine Fumarate; D044402:Receptor, Serotonin, 5-HT2A; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D007093:Imidazoles; D007211:Indoles; D044402:Receptor, Serotonin, 5-HT2A; D011954:Receptors, Dopamine; D011985:Receptors, Serotonin; D000069348:Quetiapine Fumarate; C066304:sertindole